Tune Therapeutics was founded upon cutting-edge advances in the mechanics of gene regulation. Our ‘genetic tuning’ technology enables exquisite levels of control over gene activity – activating, silencing, and fine-tuning the output of specific genes to …

Tune Therapeutics is orchestrating the power of the epigenome to treat complex, pervasive diseases that have long eluded treatment, and to unlock the full potential of regenerative medicine. Tune is pioneering a new therapeutic modality that can fine-tune any gene network.

With its unique ability to fine-tune cell properties – combined with the power to direct entire cell states, fates, and phenotypes via multiplex editing – genetic tuning opens the door to the rapid development and application of effective, regenerative therapeutics.

Jan 13, 2025 · Investors clearly appreciate the song Tune Therapeutics is singing, handing over $175 million in series B funds as the biotech takes its epigenetic silencing drug into the clinic.. The funding has ...

NOTE: Tune Therapeutics is a Duke University start-up and Duke Capital Partners portfolio company developing epigenetic editing spun out of the lab of co-founder Professor Charles Gersbach (BME, Pratt).Former Duke Biochemistry postdoc Derek Jantz is CSO.Duke Capital Partners participated in this and previous fundraising …

Tune Therapeutics isn’t the only Triangle biotech startup to have recently raised north of $100 million. In August, the Research Triangle Park-based company Pathalys Pharma secured $105 ...

Jan 13, 2025 · Launched from a Duke University lab four years ago, the biotech startup Tune Therapeutics announced a major milestone Sunday — raising $175 million in a Series B funding round to support its...

Jan 13, 2025 · Tune Therapeutics, an epigenome-editing company with origins at Duke University, has raised over $175 million in financing to advance a potential treatment for chronic hepatitis B and other diseases.

Nov 12, 2024 · Tune Therapeutics is working on an epigenetic cure for the hepatitis B virus, a leading cause of liver diseases and cancers. Photo: BSIP/Universal Images Group via Getty Images A Seattle biotech company is working on a tweak to gene expression that could shut down hepatitis B (HBV) , one of the viruses responsible for the world's most common ...

Jan 13, 2025 · Epigenome editing company Tune Therapeutics has secured more than $175 million in Series B financing to advance its “genetic tuning” platform and associated therapeutic programs. Founded in 2021, the company’s approach is focused on “activating, silencing, and fine-tuning the output of specific genes to reverse cellular dysfunction and ...